English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 29 August 2019, 11:46 JST
Share:
    

Source: Eisai
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings

TOKYO, Aug 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.

ETAK, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component of ETAK chemically binds the antimicrobial component to the area wiped with ETAK Antimicrobial Wet Wipes, preserving an antimicrobial effect that lasts for one week.

Eliminating virus and bacteria is a familiar and highly interested theme for consumers, especially mothers with small children.

There were many requests from mothers with small children such as "I want to use ETAK product not only inside the house but also the outside" and "I want to use ETAK product conveniently to the difficult to spray area. In response to these requests, ETAK Antimicrobial Wet Wipes has been commercialized. ETAK Antimicrobial Wet Wipes is alcohol-free so that it is easy to use for families with small children, and it can be used for elimination of viruses and bacteria on personal belongings as well as for cleaning hands and fingertips. In addition, wiping with this product can have antimicrobial barrier for personal belongings and prepare for virus and bacteria. The effect remains even if the area is wiped with water."

As the ETAK brand, containing long-acting antimicrobial agent ETAK, Eisai is marketing ETAK Antimicrobial Spray, a spray for mouth masks, which eliminates viruses and bacteria for 24 hours and ETAK Antimicrobial Spray alpha which can be used for a variety of lifestyle supplies including fabrics such as clothes and stuffed toys as well as kitchenware.

The addition of ETAK Antimicrobial Wet Wipes to the product lineup of ETAK brand will propose new options for elimination of viruses and bacteria as well as antimicrobial action, and we will contribute to further improvement of benefits of consumers who wish to keep those viruses and bacteria at bay.

*This product is not effective on all types of virus and bacteria.
*This product is not a pharmaceutical product nor a quasi-pharmaceutical product.
*ETAK is a registered trademark of CampusMedico Co., Ltd.

About Long-acting Antimicrobial Agent ETAK

ETAK was developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented long-acting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as an adhesive. ETAK chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect on the surface of the target object.

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Wednesday, 11 December 2024, 14:45 JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Thursday, 5 December 2024, 11:22 JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Thursday, 28 November 2024, 16:26 JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Tuesday, 26 November 2024, 15:50 JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Wednesday, 20 November 2024, 11:51 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575